Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Acumen Pharmaceuticals, Inc. (ABOS – Free Report) been one of those stocks this year? A quick glance at the company’s year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Acumen Pharmaceuticals, Inc. is a member of our Medical group, which includes 1063 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Acumen Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ABOS’ full-year earnings has moved 0.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ABOS
